Navigation Links
Eisai/Pfizer's Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimer's Disease
Date:2/4/2008

Physician Familiarity and its Better Side-Effect/Safety Profile are Driving

Aricept Prescription Rates, According to a New Report from Decision

Resources

WALTHAM, Mass., Feb. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Eisai/Pfizer's Aricept owns a dominating 42.4% patient share for first-line treatment of newly diagnosed Alzheimer's disease patients. The new report entitled Treatment Algorithms in Alzheimer's Disease finds that the reasons for favoring Aricept differ between primary care physicians and neurologists. Primary care physicians prefer Aricept over other acetylcholinesterase inhibitors (AChEIs) largely because of their familiarity with the agent, while neurologists cite Aricept's side-effect/safety profile and easier titration (the dosing schedule needed for a patient to receive full therapeutic doses of a drug).

The report finds that, in first-line treatment, Aricept holds a 42.4% patient share. The two twice-per-day AChEIs -- Novartis's Exelon and Shire/Janssen/Ortho-McNeil's Razadyne hold only 2.8% and 1.4% shares, respectively. Aricept's first-line patient share also far exceeds that of the newer formulations of those two drugs, including the once-daily formulation of Razadyne, Razadyne ER.

"Aricept's critical attribute of once-daily administration was unique until the launch of Razadyne ER in 2005," said Madhuri Borde, Ph.D., analyst at Decision Resources. "However, our survey revealed that physicians prescribe Aricept more than any other AChEI, in large part because of their comfort level with the drug, and because primary care physicians have been slow to move to Razadyne ER."

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to p
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
2. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
5. Breakthrough Opportunity for Improving Patient Health
6. Cryolife Once Again Severely Maims an Innocent Knee Surgery Patient
7. Physicians Practice, Loma Linda Partner to Improve Patient Care in Southern California
8. Difficult to Treat Erectile Dysfunction Patients
9. TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients with Acid-Related Disorders
10. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
11. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ... July 28, 2015 , ... VetStem Biopharma will be offering weekly private guided ... local area veterinarians. , The tour and course will be given every Wednesday at ... VetStem’s Poway facility. Staff members are welcome to attend with their veterinarian as well. ...
(Date:7/28/2015)... , July 28, 2015  Kerastem Technologies announce ... from the U.S. FDA Center For Biologics Evaluation and ... to conduct a clinical trial investigating the safety and ... female and early male pattern baldness (androgenic alopecia). ... trial, follows initial clinical work in Europe ...
(Date:7/28/2015)... July 28, 2015 CSL Behring ... has accepted for review the company,s Biologics License Application ... (rVIII-SingleChain) for the treatment of hemophilia A. In the ... Hemophilia A is a congenital ... nearly all affected patients are male. People with hemophilia ...
(Date:7/28/2015)... Israel , July 28, 2015 ... medicine company utilizing its proprietary plant-based rhCollagen technology ... Shurtz has been appointed Senior Director of Business ... (Photo: http://photos.prnewswire.com/prnh/20150728/246955 ) , ... in marketing, regulatory and business strategy. Prior to ...
Breaking Biology Technology:VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3CollPlant Names Shomrat Shurtz Senior Director of Business Development 2
... Biopharma: Strategies for Reaching Investors in a Financial Crisis, ... BASKING RIDGE, N.J., June 18 Biotech companies throughout ... half of the industry,s 370 small-cap funds slated to ... and investment market leaders concluded during a life sciences ...
... TORONTO, June 18 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. ... of sepsis, today announced that findings demonstrating the ... endotoxin from the bloodstream, when added to conventional ... reduced 28-day mortality in patients with severe sepsis ...
... anticipate a future event and prepare for it, according ... In a paper that appeared today in Nature ... research associate Dr. Orna Dahan of the Institute,s Molecular ... Romano of Tel Aviv University, examined microorganisms living in ...
Cached Biology Technology:Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 2Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 3Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 4Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 5Spectral announces publication demonstrating Toraymyxin(TM) significantly reduces mortality from sepsis in prospective controlled trial 2Spectral announces publication demonstrating Toraymyxin(TM) significantly reduces mortality from sepsis in prospective controlled trial 3Israeli scientists show bacteria can plan ahead 2Israeli scientists show bacteria can plan ahead 3
(Date:7/9/2015)... 07, 2015 Research ... of the "Biometrics for Banking; Market & ... report to their offering. The adoption ... this growth and the forecast is that by ... for companies involved in delivering biometric systems to ...
(Date:7/8/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), ... the launch of a study that aims to ... (PCM) technology for predicting response to treatment in ... of the novel immunotherapy agents Yervoy® (ipilumumab), a ... The 50-patient study will be led by researchers ...
(Date:7/2/2015)... June 25, 2015 ... addition of the "Natural Language Processing Market ... IVR, OCR, Pattern & Image Recognition) - Worldwide ... The key vendors occupying the market ... Corporation, Microsoft Corporation, NetBase Solutions, SAS Institute Inc., ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2
... 8, 2011Successful intranasal delivery of stem cells to ... significant improvement in motor function and reversed the ... promising findings, reported in Rejuvenation Research , ... Inc. highlight the potential for a noninvasive approach ...
... -- The University of South Florida received $5.45 million in ... grant is to create advanced devices that mimic the human ... parasite particularly the elusive liver stage where the disease ... could help accelerate the discovery of new drugs or even ...
... Journal of the American Medical Society ("Medical ... of NJIT Associate Professor Sergei Adamovich, a biomedical engineer. ... PhD, PT, and Eugene Tunik, PhD, PT, at the ... developed innovative robotic and virtual reality-based video game therapies ...
Cached Biology News:University of South Florida and Draper team to create advanced devices for testing malaria drugs 2University of South Florida and Draper team to create advanced devices for testing malaria drugs 3University of South Florida and Draper team to create advanced devices for testing malaria drugs 4JAMA features NJIT biomedical engineer helping stroke patients 2JAMA features NJIT biomedical engineer helping stroke patients 3